GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (OTCPK:CMOPF) » Definitions » Price-to-Funds-From-Operations

CMOPF (Cosmo Pharmaceuticals NV) Price-to-Funds-From-Operations : (As of Mar. 04, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Cosmo Pharmaceuticals NV Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Cosmo Pharmaceuticals NV Business Description

Address
Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.